Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry-Reference-Cited by-同舟云学术

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry

Published:2021-08 Issue:4 Volume:4 Page:618-627
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Kuppen Malou C.P.,Westgeest Hans M.,van den Eertwegh Alphonsus J.M.,van Moorselaar Reindert J.A.,van Oort Inge M.,Coenen Juleon L.L.M.,van den Bergh A.C.M. (Fons),Mehra Niven,Somford Diederik M.,Bergman Andre M.,ten Bokkel Huinink Daan,Fossion Laurent,Geenen Maud M.,Hendriks Mathijs P.,van de Luijtgaarden Addy C.M.,Polee Marco B.,Weijl Nir I.,van de Wouw Agnes J.,de Wit Ronald,Uyl-de Groot Carin A.,Gerritsen Winald R.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference28 articles.

1. Kostenprognose van Opname van Cabazitaxel (Jevtana®) in de Beleidsregel Dure Geneesmiddelen;Commissie Farmaceutische Hulp,2011

2. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer;Buttigliero;Cancer Treat Rev,2015

3. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCRPC): results for 2nd-line therapy;Khalaf;J Clin Oncol,2018

4. Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer;Matsubara;Clin Genitourin Cancer,2018

5. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies;Nadal;Prostate,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence;Cancers;2023-07-27

2. Identification of Patients With Metastatic Prostate Cancer With Natural Language Processing and Machine Learning;JCO Clinical Cancer Informatics;2022-12

3. Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2022-11

4. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial;European Journal of Cancer;2022-09

5. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study);Prostate Cancer and Prostatic Diseases;2022-02-21